These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32851872)

  • 21. One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
    Ruggiero L; Iodice R; Esposito M; Dubbioso R; Tozza S; Vitale F; Santoro L; Manganelli F
    Ther Adv Neurol Disord; 2018; 11():1756286418809588. PubMed ID: 30542376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Off-Label Use of Ataluren in Four Non-ambulatory Patients With Nonsense Mutation Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength.
    Ebrahimi-Fakhari D; Dillmann U; Flotats-Bastardas M; Poryo M; Abdul-Khaliq H; Shamdeen MG; Mischo B; Zemlin M; Meyer S
    Front Pediatr; 2018; 6():316. PubMed ID: 30406066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
    Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
    Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review.
    Pascual-Morena C; Cavero-Redondo I; Álvarez-Bueno C; Mesas AE; Pozuelo-Carrascosa D; Martínez-Vizcaíno V
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1738-1752. PubMed ID: 33325654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ataluren: first global approval.
    Ryan NJ
    Drugs; 2014 Sep; 74(14):1709-14. PubMed ID: 25193627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.
    Reddy C; Patil AN; Suthar R; Sankhyan N; Sirari T; Kumar A; Bhattacharjee S; Saxena S; Saini AG; Sahu JK
    Eur J Paediatr Neurol; 2022 May; 38():77-84. PubMed ID: 35500465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTC124, nonsense mutations and Duchenne muscular dystrophy.
    Wilton S
    Neuromuscul Disord; 2007 Oct; 17(9-10):719-20. PubMed ID: 17952895
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic approach with Ataluren in Duchenne symptomatic carriers with nonsense mutations in dystrophin gene. Results of a 9-month follow-up in a case report.
    D'Ambrosio P; Orsini C; Nigro V; Politano L
    Acta Myol; 2018 Dec; 37(4):272-274. PubMed ID: 30944907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy.
    Brogna C; Coratti G; Rossi R; Neri M; Messina S; Amico A; Bruno C; Lucibello S; Vita G; Berardinelli A; Magri F; Ricci F; Pedemonte M; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Politano L; Comi GP; Sansone VA; Albamonte E; Donati A; Bertini E; Goemans N; Previtali S; Bovis F; Pane M; Ferlini A; Mercuri E;
    Neuromuscul Disord; 2021 Jun; 31(6):479-488. PubMed ID: 33773883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.
    Welch E; Goetz D; Almstead N
    Acta Myol; 2008 Oct; 27():63-8. PubMed ID: 19364064
    [No Abstract]   [Full Text] [Related]  

  • 33. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans.
    Kong R; Ma J; Hwang S; Goodwin E; Northcutt V; Babiak J; Almstead N; McIntosh J
    Drug Metab Dispos; 2020 Apr; 48(4):317-325. PubMed ID: 31980502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Duchenne muscular dystrophy].
    Meißner T
    MMW Fortschr Med; 2015 Jul; 157(13):81. PubMed ID: 26206053
    [No Abstract]   [Full Text] [Related]  

  • 36. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
    Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
    Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Ataluren on dystrophin mutations.
    Berger J; Li M; Berger S; Meilak M; Rientjes J; Currie PD
    J Cell Mol Med; 2020 Jun; 24(12):6680-6689. PubMed ID: 32343037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
    Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
    Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.